ทวีตที่ปักหมุด
Upcoming US #FDA drug and biologic advisory committee meetings 📅 sac-tracker.com/calendar
English
SAC Tracker
14.8K posts
SAC Tracker
@FDAadcomm
Information about US FDA Scientific Advisory Committee (SAC) meetings
Washington DC เข้าร่วม Ağustos 2013
401 กำลังติดตาม7K ผู้ติดตาม
The CRDAC will discuss sNDA on September 13, 2023, for ONPATTRO lipid complex injection, submitted by @Alnylam Pharmaceuticals for the proposed treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults.
English
The Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of Palovarotene capsules, submitted by Ipsen Biopharmaceuticals for the prevention of Heterotopic ossification in adults and children with FOP.
SAC Tracker@FDAadcomm
On Wednesday, June 28, 2023, the Endocrinologic Drugs Advisory Committee will discuss new drug application (NDA-215559), for Palovarotene capsules, submitted by Ipsen Biopharmaceuticals for the prevention of heterotopic ossification in adults and children with FOP.
English
The EMDAC votes in favor of Palovarotene capsules, submitted by Ipsen Biopharmaceuticals for the prevention of Heterotopic ossification in adults and children with FOP.
SAC Tracker@FDAadcomm
On Wednesday, June 28, 2023, the Endocrinologic Drugs Advisory Committee will discuss new drug application (NDA-215559), for Palovarotene capsules, submitted by Ipsen Biopharmaceuticals for the prevention of heterotopic ossification in adults and children with FOP.
English
The PCNS advisory committee votes unanimously (6-Yes; 0- No;0-Abstain) for LEQEMBI (lecanemab), submitted by Eisai, Inc, for the treatment of Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of disease.
SAC Tracker@FDAadcomm
On Friday, June 9th, 2023, the PCNS advisory committee will discuss sBLA (761269/s-001), for Lecanemab intravenous infusion, submitted by @Eisai, for the treatment of Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of disease.
English
On Wednesday, June 28, 2023, the Endocrinologic Drugs Advisory Committee will discuss new drug application (NDA-215559), for Palovarotene capsules, submitted by Ipsen Biopharmaceuticals for the prevention of heterotopic ossification in adults and children with FOP.
English
The VRBPAC unanimously recommends on the periodic update of the current vaccine composition to a monovalent XBB-lineage for the 2023-2024 vaccination campaign.
SAC Tracker@FDAadcomm
The VRBPAC on June 15th 2023, will discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign.
English
The VRBPAC on June 15th 2023, will discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign.
English
The AMDAC votes unanimously in support of Nirsevimab submitted by @AstraZeneca for the prevention of RSV LRTD in neonates and infants born during or entering their first RSV season and in Children up to 24 months of age.
SAC Tracker@FDAadcomm
On June 8th 2023, the AMDAC will discuss a BLA for Nirsevimab, submitted by @AstraZeneca for the prevention of RSV LRTD in neonates and infants born during or entering their first RSV season and in children up to 24 months of age.
English
On Friday, June 9th, 2023, the PCNS advisory committee will discuss sBLA (761269/s-001), for Lecanemab intravenous infusion, submitted by @Eisai, for the treatment of Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of disease.
English
On June 8th 2023, the AMDAC will discuss a BLA for Nirsevimab, submitted by @AstraZeneca for the prevention of RSV LRTD in neonates and infants born during or entering their first RSV season and in children up to 24 months of age.
English
The GIDAC panel voted 15-to-1 (15- No; 1- Yes; 0- Abstain) against the approval of OCA obeticholic acid (OCA) for treating NASH patients with fibrosis
SAC Tracker@FDAadcomm
On Friday, May 18, 2023, the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting will discuss NDA- 212833 for Obeticholic acid (OCA) 25 mg oral tablets, submitted by @InterceptPharma Inc., for the treatment of pre-cirrhotic liver fibrosis due to NASH.
English
The VRBPAC panel voted unanimously (14-0) on the ABRYSVO's effectiveness, and (10 -14) voted on the safety of ABRYSVO vaccine n infants from birth through 6 months of age by active immunization of pregnant individuals.
SAC Tracker@FDAadcomm
On May 18, 2023, the VRBPAC will review BLA of ABRYSVO vaccine, submitted by @pfizer, for the prevention of LRTD and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.
English
On Friday, May 18, 2023, the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting will discuss NDA- 212833 for Obeticholic acid (OCA) 25 mg oral tablets, submitted by @InterceptPharma Inc., for the treatment of pre-cirrhotic liver fibrosis due to NASH.
English
The CTGTAC votes 8–6 (8 Yes; 6 No; 0 Abstain) in favor of SRP-9001 stating the considerations of benefit and risk, taking into account the existing uncertainties, at week 12 as a surrogate end point.
SAC Tracker@FDAadcomm
The CTGTAC on Friday May 12, 2023 will review Biologic license application (BLA 125781) submitted by @Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec for the treatment of (DMD) with a confirmed mutation in the DMD gene.
English
On May 18, 2023, the VRBPAC will review BLA of ABRYSVO vaccine, submitted by @pfizer, for the prevention of LRTD and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.
English
The CTGTAC on Friday May 12, 2023 will review Biologic license application (BLA 125781) submitted by @Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec for the treatment of (DMD) with a confirmed mutation in the DMD gene.
English
The PADAC majority votes in favor of epinephrine spray (17- Yes; 5- No; 0- Abstain) submitted by ARS Pharmaceuticals Inc., for the emergency treatment of allergic reactions (Type I) including anaphylaxis in adults and children ≥ 30 kgs.
SAC Tracker@FDAadcomm
On 11th May 2023, the Pulmonary-Allergy Drugs Advisory Committee (PADAC) will discuss NDA 214697, for epinephrine nasal spray, submitted by ARS Pharmaceuticals Inc., for the emergency treatment of allergic reactions (Type I) including anaphylaxis in adults and children ≥ 30 kgs.
English
On 11th May 2023, the Pulmonary-Allergy Drugs Advisory Committee (PADAC) will discuss NDA 214697, for epinephrine nasal spray, submitted by ARS Pharmaceuticals Inc., for the emergency treatment of allergic reactions (Type I) including anaphylaxis in adults and children ≥ 30 kgs.
English
The Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) votes unanimously (17- Yes; 0- No; 0- Abstentions) stating that the benefits of OPILL contraceptive available for OTC use outweighs the risks.
SAC Tracker@FDAadcomm
On 9th and 10th May 2023, the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee will discuss sNDA for OPILL (norgestrel) tablet, submitted by Laboratoire HRA Pharma for nonprescription use to prevent Pregnancy
English
On 9th and 10th May 2023, the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee will discuss sNDA for OPILL (norgestrel) tablet, submitted by Laboratoire HRA Pharma for nonprescription use to prevent Pregnancy
English